Mylan NV will pay $465 million fine to settle claims brought by the U.S. Justice Department that it overcharged the government for its emergency allergy drug, EpiPen.
The U.S. Attorney’s Office in Massachusetts announced the agreement on Thursday, saying it had violated the False Claims Act “by knowingly misclassifying EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid.”
French drug company Sanofi , the parent company of the state’s… (Source: bizjournals.com Health Care:Physician Practices headlines)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Mylan (NSDQ:MYL) said today that it inked a $465 million deal with U.S. Dept. of Justice to settle claims that it misclassified its EpiPen allergy auto-injector device with the Medicaid Drug Rebate Program.
In October last year, The Centers for Medicare & Medicaid Services said that Mylan had been overcharging Medicaid for its EpiPen device for years, despite being warned that it should have paid bigger rebates.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification appeared first on MassDevice. (Source: Mass Device)
BOSTON (Reuters) - Mylan NV has finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases. (Source: Reuters: Health)
Four years after children in a study took the oral treatment, 70% had no allergic reaction to peanuts. (Source: BBC News | Health | UK Edition)
Illinois Allergy and Asthma Specialists
Pediatric and Adult Allergists serving Chicago, Evanston, Skokie, and the North Shore
Evanston Location: COS Building, 2500 Ridge Ave, Suite 211A, Evanston, IL 60201
Chicago Location: Illinois Masonic Medical Office, 3000 N Halsted St # 724, Chicago, IL 60657
Phone: (847) 328-7909 Fax: (847) 328-7919